Abstract: A method for identifying drug resistant genes and compositions containing agents that downregulate these genes in combination with a cancer therapeutic.

Abstract: Disclosed herein are methods of treating and making prognostic prediction of, monitoring of therapeutic outcome for treatment of cervical carcinoma in a patient in need thereof by quantifying gene expression in a sample, wherein the genes include 10 high risk genes; calculating the subject's survival risk score by determining the protein expression levels and their relationships using machine learning (ML) and artificial intelligence. The survival risk category of a patient is determined by the consensus or plurality voting of a large number of ML models that individually have excellent predictive potential, thus providing a very robust prognostic biomarker for cervical carcinoma.

Abstract: Disclosed herein are methods of staging, treating and making prognostic prediction of, monitoring of therapeutic outcome for treatment of cervical carcinoma in a patient in need thereof by quantifying gene expression in a sample, wherein the genes include 40 high risk genes; calculating the subject's survival risk score by determining the gene expression levels and their inter-dependence using machine learning (ML) and artificial intelligence. The survival risk category of a patient is determined by the consensus or plurality voting of a large number of ML models that individually have excellent predictive potential, thus providing a very robust prognostic biomarker for cervical carcinoma.

Abstract: The application provides methods of prognosing and classifying uterine serous carcinoma (USC) patients into poor survival groups or good survival groups and for predicting response to therapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: A method for identifying drug resistant genes and compositions containing agents that downregulate these genes in combination with a cancer therapeutic.

Abstract: Biomarkers are provided that are useful for the detection or diagnosis of ovarian cancer. The biomarkers are also useful for determining whether the ovarian cancer is active, is in remission, or is recurring. Preferred biomarkers for detecting or diagnosing ovarian are provided in Table 1. Exemplary combinations of these biomarkers are described in FIGS. 2-6.

Abstract: It has been discovered that STAT5 phosphorylation and CD150 are effective biomarkers for detecting, diagnosing, and monitoring hematological malignancies, including for example lymphomas. Compositions and methods for identifying therapeutic agents for the treatment of hematologic malignancies using p-STAT5, CD150 or both as biomarkers are described.

Abstract: Methods and compositions for treating, detecting, diagnosing or assisting in the diagnosis of diabetes or diabetes-related complications are provided. Insulin-growth factor binding protein 6 (IGFBP6) has been determined to be a biomarker for type 1 diabetes (T1D) as well as for certain T1D complications such as nephropathy, retinopathy, and blindness. Compositions that prevent expression of IGFBP6 or block binding of IGFBP6 with its target, insulin-growth factor II (IGF-II), can be used to treat one or more symptoms or pathological processes of diabetes. Assaying for levels of IGFBP6 can be used to monitor disease progression, determine disease severity, and determine risk of developing diabetes or diabetes-related complications.

Abstract: Compositions and methods for determining a subject's risk of developing type 1 diabetes (T1D) and diabetic complications are provided. One embodiment provides a method involving measuring the levels of interleukin-1-receptor antagonist (IL-1ra) in a sample from the subject. In other embodiments, the method involves measuring the levels of MIP-1?, IL-8, MCP-1, MPO, SAA, IGFBP2, Adiponectin, or combinations thereof. Another embodiment provides preventing islet autoimmunity and T1D using agonist of IL-1ra, MIP-1?, IL-8, MCP-1, MPO, or a combination thereof. Another embodiment provides preventing islet autoimmunity, T1D and diabetic complications using antagonist of SAA, IGFBP2, Adiponectin, or a combination thereof.

Abstract: Antibodies selectively directed against SUM04 polypeptides are provided. The antibodies are useful research tools and further in the diagnosis and treatment of Type 1 diabetes.

Abstract: Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.

Abstract: Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.

Abstract: A new gene family involved in cell cycle regulation was discovered. This family has been termed activators of cyclin-dependent kinases (ACDKs). A number of ACDK genes have been cloned and sequenced. Proteins encoded by ACDK genes specifically were shown to interact with CDKs and pRb, and to upregulate the kinase activity of a CDK using pRb as a substrate. Progression of a cell through the cell cycle can be regulated by modulating ACDK expression in the cell.

Abstract: A new gene family involved in cell cycle regulation was discovered. This family has been termed activators of cyclin-dependent kinases (ACDKs). A number of ACDK genes have been cloned and sequenced. Proteins encoded by ACDK genes specifically were shown to interact with CDKs and pRb, and to upregulate the kinase activity of a CDK using pRb as a substrate. Progression of a cell through the cell cycle can be regulated by modulating ACDK expression in the cell.

Abstract: Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.